Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Cardiovascular risk in kidney transplant recipients receiving mammalian target of rapamycin inhibitors.

Watorek E, Szymczak M, Boratynska M, Patrzalek D, Klinger M.

Transplant Proc. 2011 Oct;43(8):2967-9. doi: 10.1016/j.transproceed.2011.08.009.

PMID:
21996202
2.

Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option?

Höcker B, Tönshoff B.

Paediatr Drugs. 2011 Feb 1;13(1):49-69. doi: 10.2165/11538530-000000000-00000. Review.

PMID:
21162600
3.

Belatacept for kidney transplant recipients.

Masson P, Henderson L, Chapman JR, Craig JC, Webster AC.

Cochrane Database Syst Rev. 2014 Nov 24;(11):CD010699. doi: 10.1002/14651858.CD010699.pub2. Review.

PMID:
25416857
4.
5.

Can we eliminate both calcineurin inhibitors and steroids?

Lebranchu Y.

Transplant Proc. 2010 Nov;42(9 Suppl):S25-8. doi: 10.1016/j.transproceed.2010.07.002. Review.

PMID:
21095446
6.

mTOR inhibitors in pediatric kidney transplantation.

Pape L, Ahlenstiel T.

Pediatr Nephrol. 2014 Jul;29(7):1119-29. doi: 10.1007/s00467-013-2505-9. Review.

PMID:
23740036
7.

What is the impact of immunosuppressive treatment on the post-transplant renal osteopathy?

Blaslov K, Katalinic L, Kes P, Spasovski G, Smalcelj R, Basic-Jukic N.

Int Urol Nephrol. 2014 May;46(5):1019-24. doi: 10.1007/s11255-013-0596-7. Review.

PMID:
24217803
8.

Clinical insights for cancer outcomes in renal transplant patients.

Alberú J.

Transplant Proc. 2010 Nov;42(9 Suppl):S36-40. doi: 10.1016/j.transproceed.2010.07.006. Review.

PMID:
21095450
9.

HMG CoA reductase inhibitors (statins) for kidney transplant recipients.

Palmer SC, Navaneethan SD, Craig JC, Perkovic V, Johnson DW, Nigwekar SU, Hegbrant J, Strippoli GF.

Cochrane Database Syst Rev. 2014 Jan 28;(1):CD005019. doi: 10.1002/14651858.CD005019.pub4. Review.

PMID:
24470059
10.

mTOR inhibitor-associated proteinuria in kidney transplant recipients.

Diekmann F, Andrés A, Oppenheimer F.

Transplant Rev (Orlando). 2012 Jan;26(1):27-9. doi: 10.1016/j.trre.2011.10.003. Review.

PMID:
22137729
11.
12.

A systematic review of conversion from calcineurin inhibitor to mammalian target of rapamycin inhibitors for maintenance immunosuppression in kidney transplant recipients.

Lim WH, Eris J, Kanellis J, Pussell B, Wiid Z, Witcombe D, Russ GR.

Am J Transplant. 2014 Sep;14(9):2106-19. doi: 10.1111/ajt.12795. Review.

13.

Risk of metabolic complications in kidney transplantation after conversion to mTOR inhibitor: a systematic review and meta-analysis.

Murakami N, Riella LV, Funakoshi T.

Am J Transplant. 2014 Oct;14(10):2317-27. doi: 10.1111/ajt.12852. Review.

14.

Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients.

Kasiske BL, de Mattos A, Flechner SM, Gallon L, Meier-Kriesche HU, Weir MR, Wilkinson A.

Am J Transplant. 2008 Jul;8(7):1384-92. doi: 10.1111/j.1600-6143.2008.02272.x. Review.

15.

Cardiovascular manifestations of allograft dysfunction in renal transplant recipients: a review.

Karbasi-Afshar R, Saburi A, Taheri S.

Arab J Nephrol Transplant. 2014 May;7(2):83-9. Review.

PMID:
25366502
16.

mTOR inhibitors and dyslipidemia in transplant recipients: a cause for concern?

Holdaas H, Potena L, Saliba F.

Transplant Rev (Orlando). 2015 Apr;29(2):93-102. doi: 10.1016/j.trre.2014.08.003. Review.

PMID:
25227328
17.

Calcineurin inhibitor minimisation versus continuation of calcineurin inhibitor treatment for liver transplant recipients.

Penninga L, Wettergren A, Chan AW, Steinbrüchel DA, Gluud C.

Cochrane Database Syst Rev. 2012 Mar 14;(3):CD008852. doi: 10.1002/14651858.CD008852.pub2. Review.

PMID:
22419339
18.

Immunosuppression minimization vs. complete drug withdrawal in liver transplantation.

Londoño MC, Rimola A, O'Grady J, Sanchez-Fueyo A.

J Hepatol. 2013 Oct;59(4):872-9. doi: 10.1016/j.jhep.2013.04.003. Review.

19.

Systemic and nonrenal adverse effects occurring in renal transplant patients treated with mTOR inhibitors.

Zaza G, Tomei P, Ria P, Granata S, Boschiero L, Lupo A.

Clin Dev Immunol. 2013;2013:403280. doi: 10.1155/2013/403280. Review.

20.

Immunosuppressive drugs after solid organ transplantation.

van Sandwijk MS, Bemelman FJ, Ten Berge IJ.

Neth J Med. 2013 Jul-Aug;71(6):281-9. Review.

Supplemental Content

Support Center